Tenon Medical Reports Fourth Quarter and Full Year 2023 Financial Results
- None.
- The company reported operating losses totaling $3.1 million for Q4 2023, and $15.7 million for the full year 2023.
- Net loss was $3.1 million for Q4 2023 and $15.6 million for the full year 2023.
- The company expects to incur additional losses in the future.
Insights
The reported growth in revenue and surgical procedures for Tenon Medical, Inc. suggests a robust demand for their Catamaran SI Joint Fusion System. A 192% year-over-year increase in Q4 revenue and a 324% increase for the full year are significant indicators of the company's market penetration and the adoption rate of their technology. The consistent positive gross profit margin, reaching 69% in Q4, reflects operational efficiency and could be a positive signal to investors about the company's ability to scale profitably.
However, despite these positive indicators, the company continues to operate at a loss, with a net loss of $3.1 million in Q4 and $15.6 million for the full year. This is not uncommon for medical device companies in the early stages of commercialization, as initial investments in R&D and market development are typically high. Investors should be mindful of the company's cash position of $2.4 million and the full repayment of a $1.2 million debt, which may affect the company's financial flexibility moving forward.
The significant increase in the number of surgical procedures utilizing the Catamaran System indicates a growing acceptance within the medical community. The 312% year-over-year increase in surgical procedures is a clear indicator of the system's clinical adoption. Moreover, the company's engagement in educational activities, such as immersive physician webinars, is a strategic move to bolster this growth by increasing product awareness and understanding among healthcare providers.
As the company plans to expand its product portfolio to address SI Revision with its patented technology, it is crucial to consider the competitive landscape and the potential market size for such innovations. The focus on post-market multi-center studies to gather important data is also a proactive approach to validate the effectiveness of their system, which could further influence market adoption and potentially drive future sales.
From a financial strategy perspective, Tenon Medical's ability to secure capital, as evidenced by the issuance of approximately $3.85 million of Series A Preferred Stock, is vital for sustaining its aggressive sales and marketing initiatives. The retirement of secured debt with these proceeds is a strategic move to improve the balance sheet and reduce financial leverage, which may be viewed favorably by investors and creditors alike.
Looking forward, the company's goal to further expand its product portfolio and refine its offerings could require substantial investment. It is essential to monitor how these initiatives will be financed and the subsequent impact on the company's cash burn rate. Additionally, the long-term value proposition for stakeholders will depend on the company's ability to transition from a growth phase to profitability, while managing the inherent risks of the medical device industry.
- Fourth Quarter 2023 Revenue Increased
192% Year-Over-Year - Full Year 2023 Revenue Increased
324% Year-Over-Year - Surgical Procedures Increased
179% Year-Over-Year in the Fourth Quarter and312% for the Full Year 2023 - Achieved Three Consecutive Quarters of Positive Gross Profit Margin in 2023
- Catamaran® SI Joint Fusion System Included in a Series of Immersive Physician Webinar Training Programs Attended by Sixty Healthcare Providers in Q4
LOS GATOS, CA / ACCESSWIRE / March 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter & Full Year 2023 and Subsequent Highlights
- Revenue of
$808,000 in the fourth quarter of 2023, a192% increase over the prior year quarter. - Revenue of
$2.9 million in 2023, a324% increase from the full year of 2022. - Gross profit increased to
$1.2 million as compared to a gross loss of ($641,000) in the full year of 2022. - Gross profit margin of
69% in the fourth quarter of 2023, a notable increase as compared to57% in Q3 2023. 312% increase in the number of surgical procedures in which the Catamaran System was used compared to the prior year.- Participated in a series of immersive physician webinar training programs featuring the Company's Catamaran® SI Joint Fusion System in Q4.
- Subsequent to year end, Tenon issued approximately
$3.85 million of Series A Preferred Stock raising approximately$2.6 million in gross proceeds and retiring$1.25 million in secured debt.
Steve Foster, President and Chief Executive Officer of Tenon Medical, commented, "Tenon's strong fourth quarter and full year of 2023 was underscored by solid momentum in revenue, gross profit and gross margin, with fourth quarter's solid performance driven by a
Our results throughout 2023, our first full year of commercialization, were driven by the successes of our sales and marketing team, and a cadence of targeted physician workshop activities including a fourth quarter webinar series attracting over sixty healthcare providers interested in the simple inferior-posterior implantation technique of our unique transfixing SI joint implant. For the full year, we hosted 133 physicians in Catamaran focused training sessions.
Additionally, throughout 2023, we successfully secured capital that has positioned our balance sheet to support our accelerated sales and marketing initiatives to advance the commercialization of the Catamaran System. We are appreciative of the confidence in our SI products as represented by our supportive and prominent investor syndicate. Importantly, our
Mr. Foster continued, "Moving into 2024, we will leverage all we've learned in our first full year of commercialization by listening intently to our physician customers. Additionally, we will expand our educational activities to encompass the full suite of applications of our unique technology and we will continue to refine our instrument and implant offerings. We continue to make progress on our post-market multi-center study and expect a preliminary glimpse of this important data in the coming weeks.
Over the long-term, our goal is to further expand our product portfolio to address SI Revision with our innovative patent protected technology. Taken together, we are proud of our 2023 accomplishments including the revenue ramp and attractive gross profit from increased awareness and adoption of The Catamaran System. We've positioned Tenon's balance sheet and operating structure to drive continued revenue growth in 2024 as we continue to pursue a long-term value proposition for all stakeholders," concluded Foster.
Fourth Quarter & Full Year 2023 Financial Results
Revenue was
Gross profit in the fourth quarter of 2023, was
Operating losses totaled
Net loss was
As of December 31, 2023, cash and cash equivalents totaled
Q4 2023 Earnings Conference Call
Management will host an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) today, Tuesday, March 12, 2024, to discuss Tenon's fourth quarter and full year 2023 financial results, provide a corporate update, and conclude with Q&A with the Company's covering analysts. To participate, please use the following information:
| Date: | Tuesday, March 12, 2024 |
| Time: | 4:30 p.m. Eastern time |
| Dial-in: | 1-877-407-0792 |
| International Dial-in: | 1-201-689-8263 |
| Webcast: | TNON Conference Call |
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
An audio playback of the call will be available through March 26, 2024, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13744319.
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Tenon is underway with a national launch of this system to address the greatly underserved market opportunity that exists in this space. For more information, please visit www.tenonmed.com.
The Tenon Medical logo and Tenon Medical, are registered trademarks of Tenon Medical, Inc. Catamaran is a trademark of Tenon Medical, Inc.
Safe Harbor
This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on Form 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
Investor Contact:
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
Tenon Medical, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except per share data)
Years Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
Revenue | $ | 2,928 | $ | 691 | ||||
Cost of sales | 1,687 | 1,332 | ||||||
Gross (Loss) Profit | 1,241 | (641 | ) | |||||
Operating Expenses | ||||||||
Research and development | 3,163 | 2,828 | ||||||
Sales and marketing | 6,778 | 7,833 | ||||||
General and administrative | 7,027 | 7,423 | ||||||
Total Operating Expenses | 16,968 | 18,084 | ||||||
Loss from Operations | (15,727 | ) | (18,725 | ) | ||||
Other Income (Expense) | ||||||||
Gain on investments | 167 | 180 | ||||||
Interest expense | (21 | ) | (354 | ) | ||||
Other expense, net | - | (18 | ) | |||||
Total Other Income (Expense), net | 146 | (192 | ) | |||||
Net Loss | $ | (15,581 | ) | $ | (18,917 | ) | ||
Net Loss Per Share of Common Stock | ||||||||
Basic and diluted | $ | (8.59 | ) | $ | (23.62 | ) | ||
Weighted-Average Shares of Common Stock Outstanding | ||||||||
Basic and diluted | 1,814 | 801 | ||||||
Consolidated Statements of Comprehensive Loss: | ||||||||
Net loss | $ | (15,581 | ) | $ | (18,917 | ) | ||
Unrealized loss on investments | 16 | (16 | ) | |||||
Foreign currency translation adjustment | 38 | 7 | ||||||
Total comprehensive loss | $ | (15,527 | ) | $ | (18,926 | ) | ||
Tenon Medical, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(In thousands, except share data)
| December 31, | December 31, | |||||||||
| 2023 | 2022 | |||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 2,428 | $ | 2,129 | ||||||
Short-term investments | - | 6,441 | ||||||||
Accounts receivable | 518 | 228 | ||||||||
Inventory | 554 | 415 | ||||||||
Prepaid expenses | 389 | 134 | ||||||||
Total current assets | 3,889 | 9,347 | ||||||||
Fixed assets, net | 961 | 793 | ||||||||
Deposits | 51 | 51 | ||||||||
Operating lease right-of-use asset | 646 | 873 | ||||||||
Deferred offering costs | 798 | 25 | ||||||||
TOTAL ASSETS | $ | 6,345 | $ | 11,089 | ||||||
| Liabilities and Stockholders' EQUITY | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | $ | 433 | $ | 550 | ||||||
Accrued expenses | 808 | 717 | ||||||||
Current portion of accrued commissions | 470 | 1,035 | ||||||||
Current portion of operating lease liability | 256 | 228 | ||||||||
Convertible notes payable and accrued interest, net of debt discount of | 1,173 | - | ||||||||
Total current liabilities | 3,140 | 2,530 | ||||||||
Accrued commissions, net of current portion | 1,999 | 1,624 | ||||||||
Operating lease liability, net of current portion | 428 | 683 | ||||||||
Total liabilities | 5,567 | 4,837 | ||||||||
Commitments and contingencies | ||||||||||
Stockholders' equity: | ||||||||||
Common stock, | 3 | 1 | ||||||||
Additional paid-in capital | 55,894 | 45,833 | ||||||||
Accumulated deficit | (55,073 | ) | (39,492 | ) | ||||||
Accumulated other comprehensive loss | (46 | ) | (100 | ) | ||||||
Total stockholders' equity | 778 | 6,252 | ||||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 6,345 | $ | 11,089 | ||||||
SOURCE: Tenon Medical, Inc.
View the original press release on accesswire.com
FAQ
What was the revenue increase for Q4 2023 compared to the prior year quarter?
How much was the revenue in full year 2023 compared to 2022?
What was the gross profit margin in Q4 2023?
What was the increase in the number of surgical procedures in 2023 compared to the prior year?
What was the purpose of the immersive physician webinar training programs in Q4?
How much capital did Tenon raise through Series A Preferred Stock issuance?
What were the operating losses for Q4 2023?
What was the net loss for the full year 2023?
What was the cash and cash equivalents balance as of December 31, 2023?
When will the Q4 2023 earnings conference call take place?
